ABSI
Absci Corp
Overview
Absci designs antibody-based therapeutics using an AI-native platform that combines generative AI models with lab validation to accelerate drug discovery.
Absci Corp is a Healthcare company operating in Biotechnology with a $1.16B market cap.
ABSI missed consensus EPS by 0.1% in Q1 FY2026, reported May 18, 2026.
10 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0716 Q&A exchanges
- Q4 FY2025Earnings2026-03-2421 Q&A exchanges
- Q3 FY2025Earnings2025-11-1221 Q&A exchanges
- Q2 FY2025Earnings2025-08-1315 Q&A exchanges
- Q1 FY2025Earnings2025-05-1320 Q&A exchanges
- Q4 FY2024Earnings2025-03-1818 Q&A exchanges
- Q3 FY2024Earnings2024-11-1211 Q&A exchanges
- Q2 FY2024Earnings2024-08-1622 Q&A exchanges
- Q1 FY2024Earnings2024-05-1418 Q&A exchanges
- Q3 FY2021Earnings2021-11-1417 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-18EPS$-0.19 vs $-0.17-10.5%Rev$215.0K vs ——EODHD
- Q4 FY20252026-03-23EPS$-0.23 vs $-0.18-27.8%Rev$650.0K vs ——EODHD
- Q3 FY20252025-11-11EPS$-0.20 vs $-0.200.0%Rev$378.0K vs ——EODHD
- Q2 FY20252025-08-11EPS$-0.24 vs $-0.21-14.3%Rev$593.0K vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.21 vs $-0.22+6.0%Rev$1.2M vs ——EODHD
- Q4 FY20242025-03-18EPS$-0.25 vs $-0.22-11.7%Rev$665.0K vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.24 vs $-0.21-14.9%Rev$1.7M vs ——EODHD
- Q2 FY20242024-08-13EPS$-0.22 vs $-0.19-15.8%Rev$1.3M vs ——EODHD
- Q1 FY20242024-05-13EPS$-0.22 vs $-0.21-4.8%Rev$898.0K vs ——EODHD
- Q4 FY20232024-03-20EPS$-0.25 vs $-0.250.0%Rev$338.0K vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.24 vs $-0.23-4.3%Rev$744.0K vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.45 vs $-0.24-87.5%Rev$3.4M vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.26 vs $-0.24-8.3%Rev$1.3M vs ——EODHD
- Q4 FY20222023-03-29EPS$-0.21 vs $-0.25+16.0%Rev$1.6M vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.30 vs $-0.28-7.1%Rev$2.4M vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.32 vs $-0.30-6.7%Rev$1.0M vs ——EODHD
- Q1 FY20222022-05-10EPS$-0.33 vs $-0.29-13.8%Rev$819.0K vs ——EODHD
- Q4 FY20212022-03-21EPS$-0.28 vs $-0.25-12.0%Rev$1.5M vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.33 vs $-0.19-73.7%Rev$1.5M vs ——EODHD
- Q2 FY20212021-09-06EPS$-2.39 vs $-0.85-100.0%Rev$728.0K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-18 | $-0.19 | $-0.17 | -10.5% | $215.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-0.23 | $-0.18 | -27.8% | $650.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.20 | $-0.20 | 0.0% | $378.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.24 | $-0.21 | -14.3% | $593.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.21 | $-0.22 | +6.0% | $1.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.25 | $-0.22 | -11.7% | $665.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.24 | $-0.21 | -14.9% | $1.7M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.22 | $-0.19 | -15.8% | $1.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.22 | $-0.21 | -4.8% | $898.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.25 | $-0.25 | 0.0% | $338.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.24 | $-0.23 | -4.3% | $744.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.45 | $-0.24 | -87.5% | $3.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.26 | $-0.24 | -8.3% | $1.3M | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.21 | $-0.25 | +16.0% | $1.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.30 | $-0.28 | -7.1% | $2.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.32 | $-0.30 | -6.7% | $1.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.33 | $-0.29 | -13.8% | $819.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-21 | $-0.28 | $-0.25 | -12.0% | $1.5M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.33 | $-0.19 | -73.7% | $1.5M | — | — | EODHD |
| Q2 FY2021 | 2021-09-06 | $-2.39 | $-0.85 | -100.0% | $728.0K | — | — | EODHD |
Source: EODHD. ABSI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ABSI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.53 | $1.11 | +37.4% | +4.8% | +4.4% |
| Q4 FY2026 | $1.35 | $1.09 | +23.8% | +4.1% | +4.3% |
| Q3 FY2026 | $1.45 | $1.16 | +24.7% | +1.6% | +0.6% |
| Q2 FY2026 | $1.55 | $1.15 | +34.9% | +3.9% | +1.0% |
| Q1 FY2025 | $1.48 | $1.17 | +26.6% | +4.4% | +4.7% |
| Q4 FY2025 | $1.81 | $1.36 | +33.0% | +2.8% | +1.1% |
| Q3 FY2025 | $1.80 | $1.36 | +32.0% | +4.3% | +1.9% |
| Q2 FY2025 | $2.02 | $1.48 | +36.7% | +2.7% | +0.2% |
| Q1 FY2024 | $1.57 | $1.23 | +27.8% | -4.6% | -1.9% |
| Q4 FY2024 | $1.93 | $1.47 | +31.1% | +7.1% | +8.4% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Sean F McClainCEO8 mo10 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
- Zachariah JonassonCFO1 yr 1 mo2 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Andreas BuschChief Innovation Officer11 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Shelby J WalkerChief Legal Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last call held guidance Q3 FY2026
- Todd BedrickSVP, CAO9 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 3/4 beats (75%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABSI.
$ curl https://api.spokenalpha.com/v1/companies/ABSIFAQ
Frequently asked about ABSI
Where can I find Absci Corp's (ABSI) earnings call transcripts?
Spoken Alpha indexes ABSI's earnings call transcripts at https://spokenalpha.com/companies/ABSI. Each call links to attributed speakers and parsed analyst Q&A. Absci Corp's own investor relations page is at https://investors.absci.com/.
When was Absci Corp's most recent earnings call?
Absci Corp (ABSI) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is ABSI in?
Absci Corp (ABSI) operates in the Healthcare sector (Biotechnology industry).